CoChat

Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes

Open access
Xu, Tao, Brandmaier, Stefan, Messias, Ana C., Herder, Christian, Draisma, Harmen H.M., Demirkan, Ayse, Yu, Zhonghao, Ried, Janina S., Haller, Toomas, Heier, Margit, Campillos, Monica, Fobo, Gisela, Stark, Renee, Holzapfel, Christina, Adam, Jonathan, Chi, Shen, Rotter, Markus, Panni, Tommaso, Quante, Anne S., He, Ying, Prehn, Cornelia, Roemisch-Margl, Werner, Kastenmüller, Gabi, Willemsen, Gonneke, Pool, René, Kasa, Katarina, van Dijk, Ko Willems, Hankemeier, Thomas, Meisinger, Christa, Thorand, Barbara, Ruepp, Andreas, Hrabé de Angelis, Martin, Li, Yixue, Wichmann, H.-Erich, Stratmann, Bernd, Strauch, Konstantin, Metspalu, Andres, Gieger, Christian, Suhre, Karsten, Adamski, Jerzy, Illig, Thomas, Rathmann, Wolfgang, Roden, Michael, Peters, Annette, van Duijn, Cornelia M., Boomsma, Dorret I., Meitinger, Thomas, Wang-Sattler, Rui · 2015 · Diabetes Care
Cited by 139

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Metformin is used as a first-line oral treatment for type 2 diabetes (T2D). However, the underlying mechanism is not fully understood. Here, we aimed to comprehensively investigate the pleiotropic effects of metformin. RESEARCH DESIGN AND METHODS: We analyzed both metabolomic and genomic data of the population-based KORA cohort. To evaluate the effect of metformin treatment on metabolite concentrations, we quantified 131 metabolites in fasting serum samples and used multivariable linear regression models in three independent cross-sectional studies (n = 151 patients with T2D treated with metformin [mt-T2D]). Additionally, we used linear mixed-effect models to study the longitudinal KORA samples (n = 912) and performed mediation analyses to investigate the effects of metformin intake on blood lipid profiles. We combined genotyping data with the identified metformin-associated metabolites in KORA individuals (n = 1,809) and explored the underlying pathways. RESULTS: We found significantly lower (P < 5.0E-06) concentrations of three metabolites (acyl-alkyl phosphatidylcholines [PCs]) when comparing mt-T2D with four control groups who were not using glucose-lowering oral medication. These findings were controlled for conventional risk factors of T2D and replicated in two independent studies. Furthermore, we observed that the levels of these metabolites decreased significantly in patients after they started metformin treatment during 7 years’ follow-up. The reduction of these metabolites was also associated with a lowered blood level of LDL cholesterol (LDL-C). Variations of these three metabolites were significantly associated with 17 genes (including FADS1 and FADS2) and controlled by AMPK, a metformin target. CONCLUSIONS: Our results indicate that metformin intake activates AMPK and consequently suppresses FADS, which leads to reduced levels of the three acyl-alkyl PCs and LDL-C. Our findings suggest potential beneficial effects of metformin in the prevention of cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc15-0658

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 139

Metadata

Authors
Xu, T., Brandmaier, S., Messias, A. C., Herder, C., Draisma, H. H. M., Demirkan, A., Yu, Z., Ried, J. S., Haller, T., Heier, M., Campillos, M., Fobo, G., Stark, R., Holzapfel, C., Adam, J., Chi, S., Rotter, M., Panni, T., Quante, A. S., He, Y., Prehn, C., Roemisch-Margl, W., Kastenmüller, G., Willemsen, G., Pool, R., Kasa, K., van Dijk, K. W., Hankemeier, T., Meisinger, C., Thorand, B., Ruepp, A., Hrabé de Angelis, M., Li, Y., Wichmann, H.-E., Stratmann, B., Strauch, K., Metspalu, A., Gieger, C., Suhre, K., Adamski, J., Illig, T., Rathmann, W., Roden, M., Peters, A., van Duijn, C. M., Boomsma, D. I., Meitinger, T., & Wang-Sattler, R.
Venue
Diabetes Care
Published
2015-06-08
Volume
38
Issue
10
Pages
1858-1867
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1824516519
Cited by
139
References
14
FWCI
5.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.